How to buy Altimmune stock | $12.95

Altimmune, Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 43 staff and has a trailing 12-month revenue of around 0.00.

Altimmune stock price (NASDAQ: ALT)

Use our graph to track the performance of ALT stocks over time.

Altimmune shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$12.95
52-week range	$7.80 - $29.71
50-day moving average	$11.90
200-day moving average	$14.19
Wall St. target price	$24.86
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.16

Buy Altimmune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Altimmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Altimmune, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Altimmune price performance over time

Historical closes compared with the close of $12.95 from 2021-06-04

1 week (2021-07-21)	N/A
1 month (2021-07-01)	28.98%
3 months (2021-04-30)	-10.50%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Altimmune financials

Revenue TTM	$6.8 million
Gross profit TTM	$-25,324,291
Return on assets TTM	-18.43%
Return on equity TTM	-41.63%
Profit margin	0%
Book value	$6.46
Market capitalisation	$360.9 million

TTM: trailing 12 months

Shorting Altimmune shares

There are currently 5.3 million Altimmune shares held short by investors – that's known as Altimmune's "short interest". This figure is 13.5% up from 4.6 million last month.

There are a few different ways that this level of interest in shorting Altimmune shares can be evaluated.

Altimmune's "short interest ratio" (SIR)

Altimmune's "short interest ratio" (SIR) is the quantity of Altimmune shares currently shorted divided by the average quantity of Altimmune shares traded daily (recently around 3.8 million). Altimmune's SIR currently stands at 1.4. In other words for every 100,000 Altimmune shares traded daily on the market, roughly 1400 shares are currently held short.

However Altimmune's short interest can also be evaluated against the total number of Altimmune shares, or, against the total number of tradable Altimmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Altimmune's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Altimmune shares in existence, roughly 140 shares are currently held short) or 0.1777% of the tradable shares (for every 100,000 tradable Altimmune shares, roughly 178 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Altimmune.

Find out more about how you can short Altimmune stock.

Altimmune share dividends

We're not expecting Altimmune to pay a dividend over the next 12 months.

Have Altimmune's shares ever split?

Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.

Altimmune share price volatility

Over the last 12 months, Altimmune's shares have ranged in value from as little as $7.8 up to $29.71. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.2938. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Altimmune overview

Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.

Frequently asked questions

What percentage of Altimmune is owned by insiders or institutions?
Currently 6.212% of Altimmune shares are held by insiders and 66.145% by institutions. How many people work for Altimmune?
Latest data suggests 43 work at Altimmune. When does the fiscal year end for Altimmune?
Altimmune's fiscal year ends in December. Where is Altimmune based?
Altimmune's address is: 910 Clopper Road, Gaithersburg, MD, United States, 20878 What is Altimmune's ISIN number?
Altimmune's international securities identification number is: US02155H2004 What is Altimmune's CUSIP number?
Altimmune's Committee on Uniform Securities Identification Procedures number is: 02155H101